SOM: Growth momentum maintained

SOMNOMED LIMITED

• Q3 FY23 revenue of $20.2 million, up 16.3% from the previous corresponding period, driven by strong demand in North American and European markets.
• Continued development of Rest Assure®, an in-built technology-enabled oral appliance, with validation and verification tests completed.
• Proactive measures taken to address supply chain challenges, focusing on securing supply and limiting inflation impact on margins.

2023-04-28 09:18:00